Answers are grounded in this paper and cite their sources.
Osteoarthritis (OA) is found secondary to medial patellar luxation (MPL) which is one of the most common diseases in small-breed dogs. Management of the disease is surgical correction or medical treatment. In patients who are unable to do the surgical correction, non-steroidal anti-inflammatory drugs (NSAIDs) remain the drugs of choice for OA therapy. Nowadays nutraceuticals have become more popular since there are no side effects when given for along period. The purpose of this study was to evaluate the clinical chondroprotective effects of undenatured collagen type-II (UCII) on osteoarthritis secondary to canine medial patellar luxation. Nine small-breed dogs (thirteen stifle joints) received UCII for 120 days. The results revealed a statistically significant difference between before and after receiving UCII in CBPI (p-value <0.05), ultrasonographic scores and joint effusion. In contrast, there was no significant difference in lameness score, radiographic examination and blood chemistry. In conclusion, UCII may be an alternative treatment for OA nutraceutical chondroprotective products which could be a co-treatment with the MPL treatment as UCII can improve the clinical signs in some dogs, which could not be managed by surgical treatment.
No takes yet. Share an insight, caveat, or question.
Kunsuwannachai et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: